The following disclosure is provided to subsection (e) of Item 5.02 of Form 8-K.

On January 9, 2020, GenMark Diagnostics, Inc. (the “Company”) notified James B. McNally, the Company’s Senior Vice President of Marketing and Business Development, that his employment with the Company would cease, effective January 10, 2020 (the “Separation Date”). On January 14, 2020 (the “Effective Date”), the Company and Mr. McNally entered into a Separation Agreement and General Release (the “Separation Agreement”), to which Mr. McNally is entitled to receive the following benefits:

to the terms of the Separation Agreement, Mr. McNally has provided the Company with a general release of all claims.

About GENMARK DIAGNOSTICS, INC. (NASDAQ:GNMK)

GenMark Diagnostics, Inc. (GenMark) is a molecular diagnostics company. The Company focuses on developing and commercializing its eSensor detection technology. Its eSensor electrochemical technology detects multiple distinct biomarkers in a single sample. It sells its XT-8 instrument and related diagnostic and research tests (XT-8 system) in the United States. It has developed and intends to commercially launch its sample-to-answer ePlex instrument and its associated diagnostic tests, which it collectively refers to as its ePlex system, in Europe and the United States. It operates in the development, manufacturing, sales and support of instruments and molecular tests based on its eSensor detection technology segment. Over four of its diagnostic tests, which run on its XT-8 instrument, have received United States Food and Drug Administration clearance, including Cystic Fibrosis Genotyping Test, Warfarin Sensitivity Test, Thrombophilia Risk Test and Respiratory Viral Panel.